Idor­sia touts new sleep drug da­ta ahead of PhI­II; Tetraphase out to raise $65M

→ Acte­lion spin­out Idor­sia says it scored pos­i­tive da­ta from two Phase II stud­ies of a new sleep drug called ACT-541468. In­ves­ti­ga­tors say that they de­signed this drug with two key fea­tures in mind: keep peo­ple asleep through the night with few lin­ger­ing side ef­fects af­ter they wake up. They test­ed the drug in 418 pa­tients, re­port­ing on top-line re­sults. And now the com­pa­ny plans to move in­to Phase III. “I am de­light­ed to see that the pos­i­tive read­outs from this com­pre­hen­sive Phase 2 pro­gram are con­sis­tent with our pre­clin­i­cal pre­dic­tive mod­els, for both adult and el­der­ly pa­tients with in­som­nia,” said CSO Mar­tine Clozel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER